clinical trial · NCT07268638
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental GlomerulosclerosisPraliciguatPlacebo
brief summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.
started
Dec 3, 2025
primary completion
Jun 1, 2027
completion
Jan 1, 2028
last updated
Apr 23, 2026
official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol